Glucagon-like peptide−1 receptor agonists (GLP-1 RAs), such as semaglutide, reduce cardiovascular risk in type 2 diabetes mellitus (T2DM), but the consistency between oral and subcutaneous formulations remains unclear. The gene discussed is GLP1R; the disease is diabetes mellitus.